Suda.Bo
SUDA.BO operates in the Pharmaceuticals industry, focusing on the development and commercialization of pharmaceutical products, and generates revenue primarily through the sale of these products to healthcare providers and consumers.
Business. SUDA.BO operates in the Pharmaceuticals industry, focusing on the development and commercialization of pharmaceutical products, and generates revenue primarily through the sale of these products to healthcare providers and consumers.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
SUDA.BO operates in the Pharmaceuticals industry, focusing on the development and commercialization of pharmaceutical products, and generates revenue primarily through the sale of these products to healthcare providers and consumers.
SUDA.BO exhibits a debt-to-equity ratio of 1.3, indicating a moderate reliance on debt financing relative to equity. The company's liquidity position is assessed as medium, with a current ratio of 1.29, suggesting it can cover its short-term obligations but with limited buffer. Free cash flow stands at INR 184.66 million, which is a positive sign for operational efficiency and financial flexibility.
In terms of profitability, SUDA.BO reports a return on equity (ROE) of 12.13%, which is a strong indicator of how effectively the company is using shareholders' equity to generate profits. However, the return on assets (ROA) of 3.96% is relatively modest, suggesting that the company may not be utilizing its assets as efficiently as it could be. These metrics should be compared against the industry median to determine if SUDA.BO is outperforming or underperforming its peers.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no significant geographic diversification reported. This concentration could pose a risk if the segment faces regulatory or market challenges. The lack of geographic diversification may also limit the company's ability to mitigate regional economic downturns.
Looking at the growth trajectory, SUDA.BO's recent financial performance shows a stable revenue trend, with no significant year-over-year changes reported. The company's capital expenditure is minimal, at INR -5.86 million, indicating a conservative approach to reinvestment. This may suggest a focus on maintaining current operations rather than aggressive expansion.
The risk assessment for SUDA.BO highlights a medium liquidity risk, primarily due to the company's current ratio and the negative net cash position after accounting for total debt. The dilution risk is assessed as low, with no significant dilution potential identified in the basic shares outstanding. However, the company's reliance on long-term debt, which amounts to INR 1.71 billion, could pose a challenge if interest rates rise or if the company's credit rating is downgraded.
Recent events, as disclosed in the company's filings, include a focus on cost optimization and operational efficiency. The company has not reported any major new product launches or strategic acquisitions in the latest financial period. The absence of significant new developments may indicate a period of consolidation or a strategic pause in expansion efforts.
- SUDA.BO has a strong ROE of 12.13%, indicating effective use of shareholders' equity.
- The company's liquidity position is moderate, with a current ratio of 1.29.
- Revenue is concentrated in a single business segment, posing potential operational risk.
- Capital expenditure is minimal, suggesting a conservative reinvestment strategy.
- The company's debt-to-equity ratio of 1.3 indicates a moderate reliance on debt financing.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- SUDA.BO Market data — financials · 2026-05-29